Tumor mutation burden derived from large NGS panel as biomarker for immunotherapy response.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e23077
Abstract: e23077Background: Tumor mutation burden (TMB) is an informative biomarker for predicting response to immunotherapy in a growing number of malignancies. The TMB clinical applicability is limited due to cost and bioinformatics requirements of sequencing and… read more here.
Keywords: tumor mutation; ngs panel; large ngs; mutation burden ... See more keywords